Document is current
Any future updates will be listed below
-
Authors
Schönenberger, Christof Manuel https://orcid.org/0000-0002-9856-3500
Speich, Benjamin
Zehnder, Elias R.
Haerry, David Hans-Ulrich
Cart-Richter, Ellen
Jackson-Perry, David
Hutter, Alissa
Aggeler, Samuel
Steinmann, Julian
Chaudron, Sandra E.
Calmy, Alexandra
Cavassini, Matthias
Braun, Dominique
Fux, Christoph A.
Abela, Irene
Kusejko, Katharina
Günthard, Huldrych F.
Nemeth, Johannes
Rauch, Andri
Wandeler, Gilles
Schmid, Patrick
Dörr, Tamara
Notter, Julia
Weisser Rohacek, Maja
Surial, Bernard
Berthet, Aurélie
Auer, Reto
Stoeckle, Marcel P.
Labhardt, Niklaus
Chammartin, Frédérique
Briel, Matthias
Amstutz, Alain
,
-
Funding
Funding for this research was provided by:
Tobacco Prevention Fonds
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (323530_221860)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (P500PM_221961)
Novartis Stiftung für Medizinisch-Biologische Forschung
Janggen-Pöhn-Stiftung
- License Information
-
More Information
Article History
Received: 5 July 2025
Accepted: 5 March 2026
First Online: 8 April 2026
Declarations
:
: RETUNE was approved by the Ethics Committee for Northern and Central Switzerland (BASEC number 2024–02417). The Swiss HIV Cohort Study was approved by the Ethics Committee Zurich (BASEC number 2023–02080).Important protocol modifications will be approved by the Ethics committee for Northern and Central Switzerland and communicated by the principal investigators. All new protocol versions will be uploaded on clinicaltrials.gov and on the RETUNE website. A concise protocol amendment history is available on the RETUNE website.
: We have no relationship with any of the product manufacturers or retailers. CMS received a travel grant from Gilead Science for another project not related to this work. BS and MB received unrestricted grants from Moderna (2021/22) for the conduct of the COVERALL-2 and COVERALL-3 study (unrelated to this project). BS has received honoraria from Moderna and Roche for presenting study results not related to this work. H. F. G. has received grants from the Swiss National Science Foundation, Swiss HIV Cohort Study, Yvonne Jacob Foundation, NIH, Gilead Sciences, ViiV and Roche; and is a subcontractor to a Bill and Melinda Gates Foundation grant (all money to institution), personal fees from Merck, Gilead Sciences, ViiV, Janssen, GSK, Johnson & Johnson, and Novartis for consultancy or data and safety monitoring board membership. All authors declare no competing interests.
